tiprankstipranks
Guardant Health (MX:GH)
NASDAQ:GH
Mexico Market

Guardant Health (GH) Stock Forecast & Price Target

Followers
See the Price Targets and Ratings of:

GH Analyst Ratings

Strong Buy
21Ratings
Strong Buy
21 Buy
0 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Guardant
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GH Stock 12 Month Forecast

Average Price Target

$3,031.83
Based on 21 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $3,031.83 with a high forecast of $3,737.18 and a low forecast of $2,172.78. The average price target represents a change from the last price of .
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"934":"$934","1635":"$1,635","2336":"$2,336","3037":"$3,037","3738":"$3,738"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3737.1806024,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.74K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3031.8277885810535,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.03K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2172.77942,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.17K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[934,1635,2336,3037,3738],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2590,2678.244661723077,2766.489323446154,2854.733985169231,2942.9786468923076,3031.2233086153847,3119.467970338462,3207.712632061539,3295.9572937846156,3384.201955507692,3472.4466172307693,3560.6912789538464,3648.9359406769236,{"y":3737.1806024,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2590,2623.9867529677736,2657.9735059355467,2691.96025890332,2725.9470118710933,2759.933764838867,2793.92051780664,2827.9072707744135,2861.8940237421866,2895.88077670996,2929.8675296777333,2963.854282645507,2997.84103561328,{"y":3031.8277885810535,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2590,2557.9061092307693,2525.8122184615386,2493.718327692308,2461.6244369230767,2429.530546153846,2397.4366553846153,2365.3427646153846,2333.248873846154,2301.154983076923,2269.061092307692,2236.9672015384613,2204.8733107692306,{"y":2172.77942,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":935,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":955.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":955.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":955.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1150,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1810,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2080,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2590,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3,737Average Price Target$3,032Lowest Price Target$2,173
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:GH
Bernstein
Bernstein
$3,476.45
Buy
Reiterated
07/22/26
Bernstein Sticks to Its Buy Rating for Guardant Health (GH)
J.P. Morgan Analyst forecast on MX:GH
J.P. Morgan
J.P. Morgan
$2,346.6$3,215.71
Buy
Reiterated
07/21/26
J.P. Morgan Reaffirms Their Buy Rating on Guardant Health (GH)
Guggenheim Analyst forecast on MX:GH
Guggenheim
Guggenheim
$2,781.16$3,302.62
Buy
Assigned
07/16/26
Guardant Health price target raised to $190 from $160 at GuggenheimGuardant Health price target raised to $190 from $160 at Guggenheim
TD Cowen
$2,207.54$3,476.45
Buy
Reiterated
07/15/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Annexon Biosciences (NASDAQ: ANNX) and Guardant Health (NASDAQ: GH)
Goldman Sachs Analyst forecast on MX:GH
Goldman Sachs
Goldman Sachs
$2,868.07$3,215.71
Buy
Reiterated
07/14/26
Goldman Sachs Sticks to Their Buy Rating for Guardant Health (GH)
Canaccord Genuity Analyst forecast on MX:GH
Canaccord Genuity
Canaccord Genuity
$2,346.6$3,563.36
Buy
Assigned
07/13/26
Guardant Health price target raised to $205 from $135 at CanaccordGuardant Health price target raised to $205 from $135 at Canaccord
Bank of America Securities Analyst forecast on MX:GH
Bank of America Securities
Bank of America Securities
$3,302.62
Buy
Reiterated
07/13/26
Guardant Health (GH) Receives a Buy from Bank of America Securities
William Blair Analyst forecast on MX:GH
William Blair
William Blair
Buy
Reiterated
07/10/26
Analyst Maintains Guardant Buy Rating, Citing Shield V2’s Competitive Edge and Strong Commercial Momentum in Colorectal Cancer Screening
Morgan Stanley Analyst forecast on MX:GH
Morgan Stanley
Morgan Stanley
$2,259.69$3,041.89
Buy
Assigned
07/09/26
Guardant Health price target raised to $175 from $130 at Morgan StanleyGuardant Health price target raised to $175 from $130 at Morgan Stanley
Citi
$2,607.34$3,737.18
Buy
Reiterated
07/08/26
Guardant Health price target raised to $215 from $150 at CitiGuardant Health price target raised to $215 from $150 at Citi
Evercore ISI Analyst forecast on MX:GH
Evercore ISI
Evercore ISI
$2,781.16$3,476.45
Buy
Reiterated
07/06/26
Guardant Health price target raised to $200 from $160 at Evercore ISIGuardant Health price target raised to $200 from $160 at Evercore ISI
Wells Fargo
$2,172.78
Buy
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Guardant Health (NASDAQ: GH)
BTIG
$2,781.16$3,302.62
Buy
Reiterated
07/01/26
UnitedHealthcare’s Early Guardant Shield Coverage Spurs Analyst to Raise Guardant Health Price Target to $190 and Reaffirm Buy Rating
Barclays Analyst forecast on MX:GH
Barclays
Barclays
$2,085.87$2,607.34
Buy
Assigned
06/24/26
Barclays Sticks to Its Buy Rating for Guardant Health (GH)
RBC Capital Analyst forecast on MX:GH
RBC Capital
RBC Capital
$3,215.71
Buy
Initiated
06/12/26
Guardant Health initiated with an Outperform at RBC CapitalGuardant Health initiated with an Outperform at RBC Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:GH
Bernstein
Bernstein
$3,476.45
Buy
Reiterated
07/22/26
Bernstein Sticks to Its Buy Rating for Guardant Health (GH)
J.P. Morgan Analyst forecast on MX:GH
J.P. Morgan
J.P. Morgan
$2,346.6$3,215.71
Buy
Reiterated
07/21/26
J.P. Morgan Reaffirms Their Buy Rating on Guardant Health (GH)
Guggenheim Analyst forecast on MX:GH
Guggenheim
Guggenheim
$2,781.16$3,302.62
Buy
Assigned
07/16/26
Guardant Health price target raised to $190 from $160 at GuggenheimGuardant Health price target raised to $190 from $160 at Guggenheim
TD Cowen
$2,207.54$3,476.45
Buy
Reiterated
07/15/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Annexon Biosciences (NASDAQ: ANNX) and Guardant Health (NASDAQ: GH)
Goldman Sachs Analyst forecast on MX:GH
Goldman Sachs
Goldman Sachs
$2,868.07$3,215.71
Buy
Reiterated
07/14/26
Goldman Sachs Sticks to Their Buy Rating for Guardant Health (GH)
Canaccord Genuity Analyst forecast on MX:GH
Canaccord Genuity
Canaccord Genuity
$2,346.6$3,563.36
Buy
Assigned
07/13/26
Guardant Health price target raised to $205 from $135 at CanaccordGuardant Health price target raised to $205 from $135 at Canaccord
Bank of America Securities Analyst forecast on MX:GH
Bank of America Securities
Bank of America Securities
$3,302.62
Buy
Reiterated
07/13/26
Guardant Health (GH) Receives a Buy from Bank of America Securities
William Blair Analyst forecast on MX:GH
William Blair
William Blair
Buy
Reiterated
07/10/26
Analyst Maintains Guardant Buy Rating, Citing Shield V2’s Competitive Edge and Strong Commercial Momentum in Colorectal Cancer Screening
Morgan Stanley Analyst forecast on MX:GH
Morgan Stanley
Morgan Stanley
$2,259.69$3,041.89
Buy
Assigned
07/09/26
Guardant Health price target raised to $175 from $130 at Morgan StanleyGuardant Health price target raised to $175 from $130 at Morgan Stanley
Citi
$2,607.34$3,737.18
Buy
Reiterated
07/08/26
Guardant Health price target raised to $215 from $150 at CitiGuardant Health price target raised to $215 from $150 at Citi
Evercore ISI Analyst forecast on MX:GH
Evercore ISI
Evercore ISI
$2,781.16$3,476.45
Buy
Reiterated
07/06/26
Guardant Health price target raised to $200 from $160 at Evercore ISIGuardant Health price target raised to $200 from $160 at Evercore ISI
Wells Fargo
$2,172.78
Buy
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Guardant Health (NASDAQ: GH)
BTIG
$2,781.16$3,302.62
Buy
Reiterated
07/01/26
UnitedHealthcare’s Early Guardant Shield Coverage Spurs Analyst to Raise Guardant Health Price Target to $190 and Reaffirm Buy Rating
Barclays Analyst forecast on MX:GH
Barclays
Barclays
$2,085.87$2,607.34
Buy
Assigned
06/24/26
Barclays Sticks to Its Buy Rating for Guardant Health (GH)
RBC Capital Analyst forecast on MX:GH
RBC Capital
RBC Capital
$3,215.71
Buy
Initiated
06/12/26
Guardant Health initiated with an Outperform at RBC CapitalGuardant Health initiated with an Outperform at RBC Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
ENOVEnovis
GKOSGlaukos
IFRXInflaRx
BKDBrookdale Senior Living
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months
William BonelloCraig-Hallum
Success Rate
10/14 ratings generated profit
71%
Average Return
+40.11%
Copying William Bonello's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +40.11% per trade.
1 Year
William BonelloCraig-Hallum
Success Rate
14/14 ratings generated profit
100%
Average Return
+139.24%
Copying William Bonello's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +139.24% per trade.
2 Years
William BonelloCraig-Hallum
Success Rate
14/14 ratings generated profit
100%
Average Return
+273.24%
Copying William Bonello's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +273.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GH Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
2
7
7
7
1
Buy
33
26
32
42
54
Hold
2
2
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
37
35
41
51
56
In the current month, GH has received 55 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. GH average Analyst price target in the past 3 months is 3,031.83.
Each month's total comprises the sum of three months' worth of ratings.

GH Financial Forecast

GH Earnings Forecast

Next quarter’s earnings estimate for GH is -$13.34 with a range of -$14.53 to -$12.08. The previous quarter’s EPS was -$14.88. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s earnings estimate for GH is -$13.34 with a range of -$14.53 to -$12.08. The previous quarter’s EPS was -$14.88. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Sales Forecast

Next quarter’s sales forecast for GH is $5.50B with a range of $5.35B to $5.64B. The previous quarter’s sales results were $5.28B. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s sales forecast for GH is $5.50B with a range of $5.35B to $5.64B. The previous quarter’s sales results were $5.28B. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Stock Forecast FAQ

What is MX:GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Guardant Health’s 12-month average price target is 3,031.83.
    What is MX:GH’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:GH, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Guardant Health a Buy, Sell or Hold?
        Guardant Health has a consensus rating of Strong Buy, which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Guardant Health’s share price target?
          The average share price target for Guardant Health is 3,031.83. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $3,737.18 ,and the lowest forecast is $2,172.78. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Guardant Health?
            Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
              How can I buy shares of Guardant Health?
              To buy shares of MX:GH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.